Home
PLRZ
PLRZ News

Latest POLYRIZON LTD (PLRZ) News on February 22, 2025

GlobeNewswire

24 days ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

GlobeNewswire

a month ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

GlobeNewswire

2 months ago

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

GlobeNewswire

2 months ago

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

GlobeNewswire

2 months ago

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

GlobeNewswire

2 months ago

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

GlobeNewswire

3 months ago

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

ACCESSWIRE

4 months ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

GlobeNewswire

4 months ago

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Share on Social Networks: